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Desloratadine is a second-generation, nonsedating H1-antihistamine that ﬁrst became available for the treatment
of allergic rhinitis (AR) in 2001; it is currently approved for
the treatment of AR irrespective of duration (intermittent/
persistent) or seasonality (seasonal/perennial) of symptoms.1Its
pharmacological characteristics are further described and
underlined in a paper published in 2004: desloratadine is
a powerful and selective H1 receptor blocker, without clini-
cally relevant pharmacokinetic interference by foods, medica-
tions, or intestinal transport proteins, nor interference with
cytochrome P 450 3A (CYP3A), and presenting additive anti-
allergic activities; these anti-inﬂammatory effects are related to
the modulation of cytokines, adhesion molecules, and effector
cells, such as eosinophils.2
From 2004 to 2009, several data concerning the use of
desloratadine and its clinical efﬁcacy in allergic respiratory
diseases have been collected and published. The results about
the desloratadine use in clinical trials are well known in both
persistent and seasonal allergic rhinitis (PAR and SAR,
according to previous classiﬁcations): the molecule has
demonstrated to be effective in relieving nasal and ocular
symptoms and improving nasal airﬂow and overall respiratory
symptoms, also referred to a concomitant asthmatic condition
(Table 1).
A paper of great interest has been published in 2007
by Canonica et al3: it is a meta-analysis of double-blind,
randomized, controlled clinical trials (performed between
January1966 and May 2006) of desloratadine efﬁcacy in the
treatment of AR in adult patients. Through a search of MED-
LINE,EMBASE,LILACS, and CINAHL databases, a total of
57 studies were collected and analyzed, and 13 randomized,
double-blind, controlled trials were included in the meta-
analysis. The studies showed a signiﬁcant heterogeneity
among their results because of the different study methodol-
ogies used. The analysis of total symptoms scores included
3108 patients: 1553 received desloratadine and 1555 placebo.
The patients assuming desloratadine presented a signiﬁcant
reduction in total symptoms scores when compared with
placebo (standardized mean difference [SMD] 21.79; 95%
CI 23.10 to 20.47;P ¼ 0.008); in a parallel manner, total
nasal symptoms score signiﬁcantly decreased in patients
treated with desloratadine versus placebo (SMD 20.66; 95%
CI: 20.91 to 20.42; P , 0.001). Only in a very small pop-
ulation (n ¼ 86), comparison with levocetirizine in terms of
total nasal symptoms was possible, but no statistical difference
between the 2 compounds was recorded (Table 2).
Concerning nasal airﬂow assessment (both after clinical
treatment and in the allergen challenge setting), 438 patients
from 7 studies were analyzed: 218 were treated with deslor-
atadine and 220 with placebo. The difference between
desloratadine and placebo resulted to be signiﬁcantly in favor
of desloratadine (SMD 0.32; 95% CI: 0.10 to 0.55; P¼ 0.005).
In terms of nasal eosinophils, 4 studies comparing
desloratadine and placebo were included, with a total number
of 133 patients: desloratadine was signiﬁcantly more effective
than placebo (SMD21.28; 95% CI22.57 to 0.01; P ¼ 0.05).
In conclusion, for the ﬁrst time this meta-analysis
demonstrates that the efﬁcacy of desloratadine versus placebo
in AR is supported by Ia evidence, the highest ranking in
evidence-based medicine. Furthermore, this is the ﬁrst meta
analysis of clinical data regarding an antihistamine that shows
signiﬁcant beneﬁcial effects not only on clinical symptoms
but also objective measures of nasal blockage and allergic
inﬂammation. The overall results support evidence of deslor-
atadine efﬁcacy in terms of improving nasal airﬂow more
than placebo and conﬁrm that nasal symptomatic beneﬁts are
accompanied by an objective decrease in nasal obstruction,
representing the main clinical feature of AR.
Focusing on intermittent allergic rhinitis (IAR), we
have to remember the ARIA document published in 20014;
the classiﬁcation in 4 categories (mild and moderate/severe
intermittent; mild and moderate/severe persistent, depending
on severity and duration of symptoms and quality of life) has
been recently conﬁrmed5 and a stepwise pharmacologic treat-
ment is proposed on the basis of ARIA clinical categories.
Recently, the authors of the last edition noted that 2 RCTs
with oral H1-antihistamines have been carried out in PER,
6,7
but no randomized controlled trials (RCTs) in IAR was pub-
lished, although one was incorrectly ascribed to IAR.8
Desloratadine is a valid therapeutic tool for allergic
rhinitis, in terms of both efﬁcacy and safety: different trials
showed that it improves symptoms and quality of life in
seasonal3,8,9 and perennial allergic rhinitis,10,11 referring to the
previous classiﬁcation. However, it has not been evaluated yet
in IAR or PER as deﬁned in the latest ARIA document.
ACCEPT-1 (Aerius Control: Clinical and Evaluative
Proﬁle of Treatment) is the ﬁrst study to test both efﬁcacy and
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safety of desloratadine in patients with IAR as deﬁned by
ARIA criteria.12 The study was conducted in collaboration
with GA2LEN (Global Allergy and Asthma European Net-
work), a consortium of the most important European research
centers specializing in allergic diseases, and was a multicenter,
multinational, randomized, double-blind, placebocontrolled,
parallel-group phase IV study of 5-mg desloratadine (orally
administered in the morning). The trial, carried out from
September 5, 2006 to November 21, 2007, involved 60
centers in 15 different countries (Belgium, Canada, Denmark,
Finland, France, Germany, Greece, Hungary, Italy, The Neth-
erlands, Portugal, Russia, Spain, Sweden, and Turkey).
TABLE 1. Recent Data About Desloratadine Use in Respiratory Diseases: Clinical Trials and End Points
Criteria Data End Point
SAR Pradalier et al. Allergy. 2007;62:1331 (AERONEF) TSS
Kosa L. JACI. 2008;121: S51 (open label) Nasal, ocular
Keith et al. Clin Ther. 2007;121;1151–1155 Nasal, ocular, respiratory, and overall symptoms
Meltzer et al. Ann Allergy Asthma Immunol.
2006;96;363–368.
TSS, nasal airﬂow




Asthma Rossi et al. Allergy. 2005; 60:416. TNSS, asthma symptoms in peds
Meta-analysis Canonica et al. Allergy. 2007;62:359. TSS, nasal airﬂow
Peds Tassinari et al. AAAAI 2006. (SAR/PAR TSS) SAR, PAR, TSS
Rossi et al. Allergy. 2005; 60:416–417 TNSS, asthma symptoms in peds
Dizdar et al. Int J Pediatr Otorhinoloaryngol.
2007;71:843–849
PRN use in peds
FIGURE 1. ACCEPT-1 study design.
TABLE 2. Comparisons of Drug Outcome for Studies Included in the Meta-Analysis
Outcome Comparison Studies (n) Patients (n) I 2 (%) Effect 95% CI P
Total symptom score DL-placebo 11 3108 99.3 21.63 22.75 to 20.51 0.004
DL-LCZ 3 86 59.9 0.54 20.20 to 1.27 0.15
Total nasal symptom score DL-placebo 7 2883 86.8 20.66 20.91 to 20.42 ,0.001
Nasal airﬂow DL-placebo 5 438 18.1 0.32 0.10 to 0.55 0.005
Nasal eosinophils DL-placebo 4 133 89.7 21.28 22.57 to 0.01 0.05
DL-LCZ 3 88 93 1.37 20.74 to 3.49 0.20
Nasal interleukin-4 DL-placebo 3 88 94.5 22.18 25.01 to 0.64 0.13
DL-LCZ 3 88 90.2 20.66 20.91 to 20.42 0.08
LCZ, levocetirizine; I2, I-square statistic; DL, desloratadine.
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The patients eligible for the study were patients 12
years of age or older, with at least a 2-year history of allergic
rhinitis symptoms deﬁned according to the International
Consensus on Rhinitis13; all the patients had to meet the
ARIA criteria for IAR (symptoms of allergic rhinitis present
,4 days per week or for ,4 consecutive weeks per year) and
present mild to moderate symptoms. The day of inclusion,
the “total score of 5 symptoms” (T5SS) had to be at least 6;
the sum of the daily averages of the diary recordings of the
12-hour morning (AM) plus evening (PM) T5SS collected for 4
days and the AM reﬂective T5SS on the morning of the ran-
domization had to be 30 at least. Allergic sensitization was
deﬁned by positive skin prick tests to common aeroallergens
carried out according to the GA2LEN skin test study.14 A
washout period for any medication for allergic rhinitis was
necessary 14 days before the patients’ randomization (Fig. 1).
Validated methods were used to enroll patients. The
primary outcome was the recommended T5SS: nasal conges-
tion stufﬁness, sneezing, rhinorrhea/nasal discharge, nasal
pruritus, and eye itching. Each sign/symptom was scored 0 to
3 (none ¼ 0 to 3 ¼ severe) and recorded in personal patients’
diaries, in the morning (AM) within 1 hour of awakening and
in the evening (PM), approximately 12 hours later. The T5SS
is the sum of the ratings for the individual scores.
The other outcomes considered were as follows:
• Symptom severity visual analog scale (VAS) assess-
ment was recorded each morning within 1 hour of
awakening and before dosing (AM) at the baseline visit
and for each day of study treatment. Scores had a range
from 0 mm (not at all bothersome) to 100 mm (very
bothersome).15,16
• Patient’s evaluation of therapeutic response to treat-
ment was assessed by the patient at the ﬁnal visit
(day 15). The evaluation considered the whole time
period since the baseline up to the ﬁnal visit, compared
with baseline. The score followed a 5-point scale: com-
plete relief, marked relief, moderate relief, slight relief,
and no relief.
• Rhinoconjunctivitis quality of life questionnaire–
standardized version (RQLQ-S) was completed by the
patient at baseline and ﬁnal visits in patients $18 years
of age. RQLQ16 was a key secondary outcome measure.
• Interference with sleep and with activities of daily living
was assessed. At the run-in visit, during the run-in period
(days 24 to 21), and continuing through the ﬁnal visit
(day 15: visit 4), patients recorded in their daily diaries
the 2 interference rating scores: AM evaluations of interfer-
ence with sleep caused by allergic rhinitis symptoms and
PM evaluations of interference with daily activities deter-
mined by allergic rhinitis symptoms during the same day.
• The allergic rhinitis speciﬁc work productivity and
activity impairment questionnaire (WPAI-AS) was com-
pleted by the patients at the baseline and through the
ﬁnal visit.17,18
• Study drug compliance with study drug was evaluated
by counting and comparing the number of tablets dis-
pensed at the baseline visit with the number returned at
the ﬁnal visit.
Instantaneous T5SS, individual symptom scores, VAS
assessments,15,16 and patient’s evaluations of response were
considered as secondary end points; WPAI-AS17,18 were used
as exploratory outcome measures.











AM/PM T5SS reﬂective 8.71 6 0.15 23.19 6 0.22 8.49 6 0.15 22.29 6 0.22 ,0.001
RQLQ total score (at end point) 2.96 6 0.08 21.10 6 0.10 2.80 6 0.08 20.73 6 0.10 ,0.001
AM/PM T5SS instantaneous 8.30 6 0.17 22.86 6 0.20 8.17 6 0.17 21.90 6 0.20 ,0.001
AM/PM rhinorrhea reﬂective 1.816 20.04 20.58 6 0.05 1.75 6 0.04 20.38 6 0.05 ,0.001
AM/PM nasal congestion reﬂective 1.96 6 0.04 20.56 6 0.05 1.87 6 0.04 20.43 6 0.05 0.013
AM/PM sneezing reﬂective 1.65 6 0.04 20.64 6 0.05 1.61 6 0.04 20.42 6 0.05 ,0.011
AM/PM nasal itching reﬂective 1.7 6 0.04 20.67 6 0.05 1.65 6 0.04 20.43 6 0.05 ,0.001
AM/PM eye itching reﬂective 1.38 6 0.06 20.58 6 0.05 1.45 6 0.06 20.46 6 0.05 0.047
AM/PM rhinorrhea instantaneous 1.76 6 0.05 20.54 6 0.05 1.72 6 0.05 20.33 6 0.05 ,0.001
AM/PM nasal congestion instantaneous 1.94 6 0.05 20.52 6 0.05 1.87 6 0.05 20.39 6 0.05 0.009
AM/PM sneezing instantaneous 1.56 6 0.05 20.59 6 0.05 1.51 6 0.05 20.36 6 0.05 ,0.001
AM/PM nasal itching instantaneous 1.65 6 0.05 20.63 6 0.05 1.61 6 0.05 20.37 6 0.05 ,0.001
AM/PM eye itching instantaneous 1.38 6 0.06 20.58 6 0.05 1.46 6 0.06 20.45 6 0.05 0.023
Sleep interference 1.37 6 0.06 20.39 6 0.05 1.38 6 0.06 20.27 6 0.05 0.039
Activity interference 1.72 6 0.05 20.60 6 0.06 1.66 6 0.05 20.40 6 0.06 ,0.001
Symptom severity reﬂective (VAS) 57.4 6 1.36 217.2 6 1.50 56.76 6 1.35 210.9 6 1.49 ,0.001
Patient’s evaluation of response WPAI-AS NA 3.24 6 20.10 NA 3.66 6 20.10 ,0.001
overall work impairment 46.38 6 2.35 215.0 6 2.78 41.37 6 2.27 25.7 6 2.69 0.002
activity impairment 48.24 6 1.85 215.3 6 2.20 46.04 6 1.87 29.2 6 2.22 0.007
AM, morning; PM, evening; DL, desloratadine; LS, least signiﬁcant. LS means, SEM (SEM of the LS means) are obtained from an ANOVA model with treatment and site effects.
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A total of 262 patients treated with desloratadine (the
active group) and 256 individuals treated with placebo
completed the study.
The results clearly show that desloratadine provided
a 24-hour efﬁcacy, as already known, signiﬁcant at day 1 and
lasting throughout the study. Nevertheless, the maximum
effect was registered after 1 week of treatment for the primary
outcome measure; it is possible that the intermittent nature of
the symptoms could have a role in attenuating the treatment
differences between the 2 groups. The efﬁcacy of deslorata-
dine was found for both instantaneous and reﬂective symp-
toms. A 37.7% change in T5SS reﬂective in the desloratadine
group and a 27.8% change in the placebo group (P , 0.001)
were recorded.
For VAS, a signiﬁcant difference was demonstrated at
day 1 and continued throughout the study. The mean baseline
VAS ratings were 57.4 in the desloratadine group and 56.7 in
the placebo group: the patients mostly presented moderate to
severe symptoms. At the end of the study, patients in the
desloratadine group showed a signiﬁcantly greater improve-
ment in VAS rating compared with placebo (Table 3, Fig. 2).
RQLQ was signiﬁcantly improved in the active group
with respect to the placebo group. Mean total RQLQ-S score
at baseline was 2.96 in the desloratadine group and 2.80 in the
placebo group, thus conﬁrming that patients presented
moderate to severe IAR; at the study end, total RQLQ global
score was signiﬁcantly improved. All RQLQ evaluations,
except for sleep, were signiﬁcantly improved in the deslor-
atadine group, if compared with placebo. Globally, all the
secondary and exploratory outcomes were also signiﬁcantly
improved by desloratadine.
In addition, all nasal symptoms were signiﬁcantly
improved in the patients treated with desloratadine, compared
with placebo. Nasal congestion relief probably is strictly
related to sleep scores improvement.
The symptoms related to AR may determine a consider-
able impairment of subjective quality of life, in terms of
physical and emotional comfort and functional capacity, with
consequent fatigue, absenteeism, and poor task perfor-
mance.19 The ACCEPT-1 is also the ﬁrst study to provide
that clinical improvement with desloratadine treatment has an
economically relevant impact on the productivity of patients
with IAR. Through the objective WPAI-AS assessment, for
the ﬁrst time a signiﬁcantly greater increase in work and
school productivity and improvement of daily activity was
evidenced in patients treated with desloratadine with respect
to placebo. In the United States, AR has been estimated to be
responsible for about 2 million school days missed and 3.5
million lost work days annually, with consequent decreased
productivity and a large economical impact.20
In addition, adverse events were comparable in the
patients of the 2 groups: desloratadine and placebo was well
tolerated and the rate of severe adverse events was identical
and very low in the 2 groups. No life-threatening adverse
event was recorded; only 4 adverse events in each group led
to a stop in treatment.
The efﬁcacy of desloratadine according to ARIA
classiﬁcation was conducted not only in patients affected by
IAR but also in those affected by PER.
According to the ARIA guidelines, PER is present
.4 days per week and for .4 consecutive weeks per year.15
This innovative classiﬁcation is closer to real life and takes
into consideration patients’ quality of life. Quality-of-life
(QoL) outcomes are an important way to measure the nega-
tive effects of AR on patients in a way that is not limited to
assessments of only sign and symptom severity, but also
includes effects of the disease and treatment on the patient.
In the study of persistent allergic rhinitis, the RQLQ is the
most frequently used tool and has been validated in many
studies and in different languages. The RQLQ-S provides
information on the impact of AR and allergic conjunctivitis
on a variety of domains that include emotions, practical prob-
lems, activities, and also nasal and other symptoms.
Desloratadine is a second-generation nonsedating anti-
histamine with both antihistaminic and anti-inﬂammatory
properties.21 Desloratadine (DL) is effective and safe in the
FIGURE 2. Evolution of reflective T5SS (a) and symptom
severity by VAS (b).
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treatment of persistent allergic rhinitis. There is Ia evidence
according to a meta-analysis of the literature about DL efﬁ-
cacy to improve nasal airﬂow, total symptoms and total nasal
symptoms.22
Although desloratadine has been shown to be safe and
effective in the treatment of seasonal and perennial AR,
ACCEPT-223 was the ﬁrst prospective study of desloratadine in
ARIA-deﬁned PER. It has a similar study design to ACCEPT-1,
previously conducted for intermittent allergic rhinitis.
The aim of the study was to evaluate the safety and the
efﬁcacy of desloratadine in this population. This multicenter,
multinational, randomized, double-blind, placebo-controlled,
parallel-group phase IV study of DL (5 mg, once daily, in the
morning) was conducted with the collaboration of GA2LEN
research centers at 83 sites in 15 countries.22 The study report
conformed to the CONSORT (CONsolidated Standards of
Reporting Trials) Statement.24
Patients aged 12 years or older had to have at least a 2-
year history consistent with symptoms of allergic rhinitis
deﬁned according to the International Consensus on Rhinitis3
and PER with moderate to severe symptoms according to the
ARIA classiﬁcation15 to be included.
At the inclusion (the start of the run-in period) the T5SS
had to reach a score of 8 at least. The sum of the daily
averages of the diary recordings of the 12-hour AM plus PM
reﬂective T5SS collected for 4 days and the AM reﬂective
T5SS on the morning of randomization had to be $40.
The study design provided a run-in period lasting from
4 to 14 days. All the patients enrolled were randomized to
receive 5-mg DL or placebo for 12 weeks. Visits took place
on day 1 (baseline visit) and days 15, 29, 43, 57, and 85 after
randomization during the treatment period (Fig. 3).
Rescue medications, such as cromoglycate (nasal and/
or ocular), were allowed after the ﬁrst 4 weeks at
the minimum dose required to control symptoms.
The primary objective was to compare the efﬁcacy and
safety of 5-mg desloratadine once daily versus placebo in
patients with PER and the primary end point was the
reﬂective T5SS in the intent-to-treat population from day 1
to day 29. The ﬁrst key secondary end point was the mean
change from baseline in RQLQ-S11 after 29 days of treatment.
The other key secondary end point was the change from
baseline in the 12-hour AM/PM reﬂective T5SS averaged dur-
ing the 12weeks of treatment (day 1 to day 85).
The instantaneous T5SS (days 1–29 and days 1–85),
individual symptom scores (days 1–29 and days 1–85),
VAS levels (days 1–29 and days 1–85),25,26 RQLQ (days
1–85), and patients’ assessment of response (days 29 and
85) were considered as secondary end points. The WPAI-
AS (days 29 and 85)27,14 was an exploratory outcome
measure.
Adverse events were recorded at each visit on the case
report form. The 931 patients were screened and 716 of them
were randomized in the clinical trial. A total of 301 patients
treated with DL and 261 patients receiving placebo completed
the study.
The mean reduction from baseline in T5SS achieved
with desloratadine during days 1–29 (3.76 points) was signif-
icantly greater if compared with placebo. The study also met
this key secondary end point, with a statistically signiﬁcantly
greater decrease from baseline in mean AM/PM PRIOR T5SS
across days 1–85 as compared with placebo. Similarly, these
results achieved with desloratadine during the ﬁrst 2 weeks
and the ﬁrst month of the study were signiﬁcantly greater than
placebo. Notably, this effect had an early onset of action,
being seen as early as day 1 of the study. The signiﬁcantly
greater effect of desloratadine on T5SS lasted through the end
of the 24-hour dosing interval, as shown here using the AM
NOW T5SS scores. The 24-hour duration of effect of deslor-
atadine was signiﬁcantly longer than placebo from day 3 of
FIGURE 3. ACCEPT-2 study design
Villa et al WAO Journal  January 2012
S10  2012 World Allergy Organization
the study and endured across the full 12-week duration for
days 2–85.
Nasal congestion is a cardinal symptom of allergic
rhinitis, difﬁcult to treat and bothersome for the patient.
Desloratadine has been shown previously to have a consis-
tently beneﬁcial effect on nasal congestion in seasonal/
perennial allergic rhinitis, but had not previously been studied
in the setting of ARIA-deﬁned PER.
Similarly, the total RQLQ-S score was signiﬁcantly
improved from baseline in the desloratadine group versus
placebo at the end of the ﬁrst month of the study, an effect
that lasted through to the end of the study at day 85 (12
weeks). When the individual domains that constitute the
RQLQ-S were assessed on their own, apart from non-nose/
eye symptoms, desloratadine treatment was shown to lead
to a statistically signiﬁcantly greater improvement in QOL
as compared with placebo at the end point analysis. Sig-
niﬁcant differences between the active and the control group
were registered with a P , 0.038 for the following domains:
activity, sleep, practical problems, nasal symptoms, eye
symptoms, and emotion.
In previous studies about the use of desloratadine in the
treatment of patients with seasonal/perennial allergic rhinitis,
desloratadine has been shown repeatedly to reduce rhinitisin-
duced impairment of sleep and daily activities. To date, these
effects of desloratadine had not been studied in thesetting of
ARIA-deﬁned PER.
As early as day 1 and for the whole duration of the
study, desloratadine treatment was associated with a statisti-
cally signiﬁcantly greater reduction in PER-induced interfer-
ence with daily activities as compared with placebo.
Similarly, desloratadine led to a statistically signiﬁcant
beneﬁcial effect in improving PER-induced sleep disturbance
during the ﬁrst month of the study and across the 12-week
duration of the study.
Allergic rhinitis is a large burden for the patient
because of impairment of sleep/daily activities and
reduced QoL. The statistically signiﬁcant effect of deslor-
atadine in reducing the burden of allergic rhinitis was
measured using the new VAS tool. Desloratadine signif-
icantly decreased the VAS severity (0 ¼ not bothersome,
100 ¼ very bothersome) from baseline from the ﬁrst
study time point (day 2 for VAS), which progressively
improved, remaining statistically superior to placebo dur-
ing the 12-week course of the study (Fig. 4, Table 4).
Desloratadine was well tolerated and no life-threatening
adverse events occurred.
In patients with intermittent (ACCEPT-1) and persis-
tent (ACCEPT-2) allergic rhinitis, therapy with deslorata-
dine provides a rapid, effective, and sustained relief of total
and individual symptom scores, including nasal congestion.
DL proved to have a 24-hour efﬁcacy with signiﬁcant
improvement in daily activities and sleep, overall quality of
life, work, or school productivity. DL provides a good
safety and tolerability proﬁle and does not present anticho-
linergic activity, sedative effects, or cognitive or psycho-
motor impairment. Desloratadine thus satisﬁes all the
ARIA/EAACI criteria16,18 and is highly recommended as
ﬁrst-line treatment in both intermittent and persistent aller-
gic rhinitis.
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